Home・Aandelen Lijst・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

3.21 1.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.17

Max

3.26

Belangrijke statistieken
By Trading Economics
Inkomsten	-9.4M -118M
Verkoop	-29M 6.5M
EPS	-0.22
Winstmarge	-1,815.575
Werknemers	600
EBITDA	-13M -102M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+104.4% upside

Dividenden
By Acuity
Volgende Winsten	4 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-180M 1.7B
Vorige openingsprijs	1.95
Vorige sluitingsprijs	3.21

Recursion Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

6 aug 2026, 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

5 aug 2026, 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

4 aug 2026, 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

3 aug 2026, 20:03 UTC

Correlated Moves

News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

31 jul 2026, 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

30 jul 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

29 jul 2026, 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

28 jul 2026, 23:11 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares declined in after-market hours, influenced by a broader market downturn and declines in tech stocks amid AI investment concerns.

27 jul 2026, 23:46 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market trends despite gains in the DAX 30 Index amid mixed results across indices.

24 jul 2026, 23:11 UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

23 jul 2026, 19:16 UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

22 jul 2026, 23:36 UTC

Recursion Pharmaceuticals Inc. shares are near unchanged in after-market hours. The stock remains below its 20-day moving average amid rising crude oil prices.

21 jul 2026, 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

20 jul 2026, 19:46 UTC

Correlated Moves

Recursion Pharmaceuticals is declining, continuing a trend from previous sessions, amid broader declines in the ARK Genomic Revolution ETF and Russell 2000 Index.

Peer Vergelijking

Prijswijziging

Recursion Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

104.4% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.5 USD 104.4%

Hoogste 8 USD

Laagste 5.5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Recursion Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Recursion Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.